5 completed, 4 active not recruiting, 3 not yet recruiting, 3 recruiting. 17 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 5, Active not recruiting 4, Not yet recruiting 3, Recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Chronic Rhinosinusitis With Nasal Polyps: new trials by email Literature Review of Chronic Rhinosinusitis With Nasal Polyps trials Research Report on Chronic Rhinosinusitis With Nasal Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps MG-K10, Placebo, Mometasone Furoate Nasal Spray - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 210 | 2026-10-27 | 2026-10-29 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Withdrawn | Sanofi | 2026-05-08 | 2026-08-13 | |
| A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Recruiting | AstraZeneca | 230 | 2026-04-24 | 2026-10-16 |
| An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 59 | 2026-03-12 | 2026-10-13 |
| A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis CM326 injection, Placebo of CM326 - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | 212 | 2026-02-28 | 2026-02-19 |
| Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps SHR-1905 Injection, SHR-1905 Placebo Injection - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 280 | 2025-08-28 | 2025-11-17 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 231 | 2025-02-12 | 2026-10-21 |
| A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS) - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | Sanofi | 216 | 2025-02-06 | 2026-10-21 |
| Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma Tezepelumab - Asthma, Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Not yet recruiting | Dr. Andrew Thamboo, MD | 10 | 2025-01-01 | 2024-12-18 |
| A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab Tezepelumab - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | AstraZeneca | 181 | 2024-12-03 | 2026-11-03 |
| Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis (CRS). Sinonasal microbiome transplant procedure., Placebo saline transplant - Chronic Rhinosinusitis Without Nasal Polyps, Chronic Rhinosinusitis With Nasal Polyps | Phase 2 / Phase 3 | Recruiting | Region Skane | 50 | 2024-10-14 | 2025-09-22 |
| A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps GR1802, Placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 228 | 2024-09-19 | 2026-10-29 |
| Dupilumab in Chinese Adult Participants With CRSwNP Dupilumab, Placebo, Budesonide - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | Sanofi | 63 | 2023-05-16 | 2025-09-25 |
| Role of Doxycycline in Chronic Rhinosinusitis With Nasal Polyps Doxycycline 100 mg Oral Tablet, Prednisolone 20 mg - Nasal Polyps, Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | Assiut University | 60 | 2021-07-01 | 2024-08-13 |
| The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Budesonide, Prednisone, Saline - Chronic Rhinosinusitis With Nasal Polyps | Phase 2 / Phase 3 | Completed | Kafrelsheikh University | 120 | 2021-05-01 | 2023-07-05 |
| Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Completed | AstraZeneca | 416 | 2021-04-22 | 2026-01-27 |
| Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Vitamin D, Budesonide Nasal Spray, placebo - Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Unknown | The First Affiliated Hospital of Shanxi Medical University | 40 | 2016-05-01 | 2016-12-06 |
Nasal Polyps (2) · Asthma (1) · Rhinosinusitis (1)
Respiratory Tract Diseases (4) · Nose Diseases (3) · Otorhinolaryngologic Diseases (3) · Pathological Conditions, Anatomical (2) · Pathological Conditions, Signs and Symptoms (2) · Polyps (2) · Bronchial Diseases (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Infections (1) · Lung Diseases (1) · Lung Diseases, Obstructive (1) · Paranasal Sinus Diseases (1) · Respiratory Hypersensitivity (1)
itepekimab (4) · Budesonide (3) · tezepelumab (3) · Doxycycline (1) · Mometasone Furoate (1) · Prednisolone (1) · Prednisone (1) · Sodium Chloride (1) · Tablets (1) · Vitamin D (1) · dupilumab (1)
Sanofi (5) · AstraZeneca (3) · Assiut University (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Dr. Andrew Thamboo, MD (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Kafrelsheikh University (1) · Region Skane (1) · Shanghai Mabgeek Biotech.Co.Ltd (1) · The First Affiliated Hospital of Shanxi Medical University (1)
China (8) · Canada (5) · Hungary (5) · Poland (5) · United States (5) · Germany (4) · Spain (4) · United Kingdom (4) · Argentina (3) · Chile (3) · Italy (3) · Japan (3) · Australia (2) · Austria (2) · Brazil (2)
Aly Ragaie (1) · Andrew Thamboo (1) · Brian Lipworth, MD (1) · Chengshuo Wang, Professor (1) · Dehui Wang (1) · Enrico Heffler, MD, PhD (1) · Hamza El Shafie (1) · Joseph K Han, MD (1) · Luo Zhang, Doctor (1) · Luo Zhang, Professor (1) · Mai AbuElmagd (1) · Tanya M Laidlaw, MD (1)
PMID 40106374, PMID 42299713, PMID 42868896
2025 (1)